FDA Developing Guidance On Exploratory INDs; Lilly Endorses Concept
FDA is developing a guidance on "exploratory" investigational new drug applications that will simplify toxicology requirements for "pre-Phase I" human trials, Clinical Pharmacology Lab Director Jerry Collins, PhD, said during an FDA workshop Nov. 16
You may also be interested in...
Radioactive drug research committee study regulations should be changed to differentiate pediatric age groups, Columbia University Professor of Radiation Biophysics Eric Hall told FDA
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011